Cargando…

Allostery governs Cdk2 activation and differential recognition of CDK inhibitors

Cyclin-dependent kinases (CDKs) are the master regulators of the eukaryotic cell cycle. To become activated, CDKs require both regulatory phosphorylation and binding of a cognate cyclin subunit. We studied the activation process of the G1/S kinase Cdk2 in solution and developed a thermodynamic model...

Descripción completa

Detalles Bibliográficos
Autores principales: Majumdar, Abir, Burban, David J., Muretta, Joseph M., Thompson, Andrew R., Engel, Tiffany A., Rasmussen, Damien M., Subrahmanian, Manu V., Veglia, Gianluigi, Thomas, David D., Levinson, Nicholas M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990704/
https://www.ncbi.nlm.nih.gov/pubmed/33526892
http://dx.doi.org/10.1038/s41589-020-00725-y
_version_ 1783669112229068800
author Majumdar, Abir
Burban, David J.
Muretta, Joseph M.
Thompson, Andrew R.
Engel, Tiffany A.
Rasmussen, Damien M.
Subrahmanian, Manu V.
Veglia, Gianluigi
Thomas, David D.
Levinson, Nicholas M.
author_facet Majumdar, Abir
Burban, David J.
Muretta, Joseph M.
Thompson, Andrew R.
Engel, Tiffany A.
Rasmussen, Damien M.
Subrahmanian, Manu V.
Veglia, Gianluigi
Thomas, David D.
Levinson, Nicholas M.
author_sort Majumdar, Abir
collection PubMed
description Cyclin-dependent kinases (CDKs) are the master regulators of the eukaryotic cell cycle. To become activated, CDKs require both regulatory phosphorylation and binding of a cognate cyclin subunit. We studied the activation process of the G1/S kinase Cdk2 in solution and developed a thermodynamic model that describes the allosteric coupling between regulatory phosphorylation, cyclin binding, and inhibitor binding. The results explain why monomeric Cdk2 lacks activity despite sampling an active-like state, reveal that regulatory phosphorylation enhances allosteric coupling with the cyclin subunit, and show that this coupling underlies differential recognition of Cdk2 and Cdk4 inhibitors. We identify an allosteric hub that has diverged between Cdk2 and Cdk4 and show that this hub controls the strength of allosteric coupling. The altered allosteric wiring of Cdk4 leads to compromised activity toward generic peptide substrates, and comparative specialization toward its primary substrate Retinoblastoma (RB).
format Online
Article
Text
id pubmed-7990704
institution National Center for Biotechnology Information
language English
publishDate 2021
record_format MEDLINE/PubMed
spelling pubmed-79907042021-08-01 Allostery governs Cdk2 activation and differential recognition of CDK inhibitors Majumdar, Abir Burban, David J. Muretta, Joseph M. Thompson, Andrew R. Engel, Tiffany A. Rasmussen, Damien M. Subrahmanian, Manu V. Veglia, Gianluigi Thomas, David D. Levinson, Nicholas M. Nat Chem Biol Article Cyclin-dependent kinases (CDKs) are the master regulators of the eukaryotic cell cycle. To become activated, CDKs require both regulatory phosphorylation and binding of a cognate cyclin subunit. We studied the activation process of the G1/S kinase Cdk2 in solution and developed a thermodynamic model that describes the allosteric coupling between regulatory phosphorylation, cyclin binding, and inhibitor binding. The results explain why monomeric Cdk2 lacks activity despite sampling an active-like state, reveal that regulatory phosphorylation enhances allosteric coupling with the cyclin subunit, and show that this coupling underlies differential recognition of Cdk2 and Cdk4 inhibitors. We identify an allosteric hub that has diverged between Cdk2 and Cdk4 and show that this hub controls the strength of allosteric coupling. The altered allosteric wiring of Cdk4 leads to compromised activity toward generic peptide substrates, and comparative specialization toward its primary substrate Retinoblastoma (RB). 2021-02-01 2021-04 /pmc/articles/PMC7990704/ /pubmed/33526892 http://dx.doi.org/10.1038/s41589-020-00725-y Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Majumdar, Abir
Burban, David J.
Muretta, Joseph M.
Thompson, Andrew R.
Engel, Tiffany A.
Rasmussen, Damien M.
Subrahmanian, Manu V.
Veglia, Gianluigi
Thomas, David D.
Levinson, Nicholas M.
Allostery governs Cdk2 activation and differential recognition of CDK inhibitors
title Allostery governs Cdk2 activation and differential recognition of CDK inhibitors
title_full Allostery governs Cdk2 activation and differential recognition of CDK inhibitors
title_fullStr Allostery governs Cdk2 activation and differential recognition of CDK inhibitors
title_full_unstemmed Allostery governs Cdk2 activation and differential recognition of CDK inhibitors
title_short Allostery governs Cdk2 activation and differential recognition of CDK inhibitors
title_sort allostery governs cdk2 activation and differential recognition of cdk inhibitors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990704/
https://www.ncbi.nlm.nih.gov/pubmed/33526892
http://dx.doi.org/10.1038/s41589-020-00725-y
work_keys_str_mv AT majumdarabir allosterygovernscdk2activationanddifferentialrecognitionofcdkinhibitors
AT burbandavidj allosterygovernscdk2activationanddifferentialrecognitionofcdkinhibitors
AT murettajosephm allosterygovernscdk2activationanddifferentialrecognitionofcdkinhibitors
AT thompsonandrewr allosterygovernscdk2activationanddifferentialrecognitionofcdkinhibitors
AT engeltiffanya allosterygovernscdk2activationanddifferentialrecognitionofcdkinhibitors
AT rasmussendamienm allosterygovernscdk2activationanddifferentialrecognitionofcdkinhibitors
AT subrahmanianmanuv allosterygovernscdk2activationanddifferentialrecognitionofcdkinhibitors
AT vegliagianluigi allosterygovernscdk2activationanddifferentialrecognitionofcdkinhibitors
AT thomasdavidd allosterygovernscdk2activationanddifferentialrecognitionofcdkinhibitors
AT levinsonnicholasm allosterygovernscdk2activationanddifferentialrecognitionofcdkinhibitors